araag2/HINT huggingface dataset:
Clinical trial NCT02349295 (phase 3, status: completed)
Conditions: psoriatic arthritis
ICD codes: L40.52
Drugs: placebo, ixekizumab 80 mg q4w, ixekizumab 80 mg q2w
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Presents with established diagnosis of active psoriatic arthritis (PsA) for at least 6
             months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria

          -  Active PsA defined as the presence of at least 3 tender and at least 3 swollen joints

          -  Presence of active psoriatic skin lesion or a history of plaque psoriasis (Ps)

          -  Men must agree to use a reliable method of birth control or remain abstinent during
             the study

          -  Women must agree to use reliable birth control or remain abstinent during the study
             and for at least 12 weeks after stopping treatment

          -  Have been treated with 1 or more conventional disease-modifying antirheumatic drugs
             (cDMARDs)

          -  Have had prior treatment with at least 1 and not more than 2 tumor necrosis factor
             (TNF) inhibitors. The participant must have discontinued at least 1 TNF inhibitor due
             to either an inadequate response (based on a minimum of 12 weeks on therapy) or
             documented intolerance.

        Exclusion Criteria:

          -  Current use of biologic agents for treatment of Ps or PsA

          -  Inadequate response to greater than 2 biologic DMARDs

          -  Current use of more than one cDMARDs

          -  Diagnosis of active inflammatory arthritic syndromes or spondyloarthropathies other
             than PsA

          -  Have received treatment with interleukin (IL) -17 or IL12/23 targeted monoclonal
             antibody (MAb) therapy

          -  Serious disorder or illness other than psoriatic arthritis

          -  Serious infection within the last 3 months

          -  Breastfeeding or nursing (lactating) women
Clinical trial NCT02354222 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: canagliflozin, teneligliptin, placebo
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, [H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCSC1)N1CCN(CC1)C1=CC(C)=NN1C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women who are 20 - 75 years old

          -  HbA1c of ≥7.0% and <10.5%

          -  FPG of ≤ 270 mg/dL

          -  Patients who are under dietary management and taking therapeutic exercise for diabetes
             over 8 weeks before run-in period

        Exclusion Criteria:

          -  Patients with type I diabetes, diabetes mellitus resulting from pancreatic disorder,
             or secondary diabetes

          -  Patients with serious diabetic complications

          -  Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria

          -  Patients with Class III/IV heart failure symptoms according to New York Heart
             Association (NYHA) functional classification

          -  Patients with severe hepatic disorder or severe renal disorder.
Clinical trial NCT02354352 (phase 3, status: completed)
Conditions: duchenne muscular dystrophy
ICD codes: G71.01
Drugs: eplerenone, spironolactone
SMILES: [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC, CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Boys age ≥7 years with DMD confirmed clinically and by mutation analysis able to
             undergo cardiac magnetic resonance (CMR) without sedation

          -  LV EF ≥45% (+/-5%) by clinically-acquired echocardiography, nuclear scan or cardiac
             MRI done within 2 weeks of enrollment

        Exclusion Criteria:

          -  Non-MR compatible implants

          -  Severe claustrophobia

          -  Gadolinium contrast allergy

          -  Kidney disease

          -  Prior use of or allergy to aldosterone antagonist

          -  Use of other investigational therapy.
Clinical trial NCT02355925 (phase 3, status: completed)
Conditions: infertility
ICD codes: N46.8, N46.9, N97.9, N97.0, N97.1, N97.2, N97.8
Drugs: intrauterine injection of uhcg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with history of one fresh embryo transfer failure

          2. Patients with Primary infertility

          3. Patients with at least one embryo with excellent quality

        Exclusion Criteria:

        1. Female age over 40 years old 2- Severe male factor (Azoospermia) 3- Endometriosis
        diagnosis and the presence of hydrosalpinges 4- Uterine factor ( polyps, myoma and previous
        myomectomy, …) 5- Patients with polycystic ovarian syndrome diagnosis 6- Cases with
        pre-implantation genetic diagnosis (PGD)indication 7- Cases with difficult embryo transfer
        or use of Tenaculum 8- Patients with repeated implantation failures and repeated
        miscarriages. 9- Female smokers
Clinical trial NCT02357069 (phase 3, status: unknown status)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: enbrel, lbec0101
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or Female patients from 20 years to 75 years of age when signing Informed
             Consent.

          -  Diagnosed as having RA according to the revised 1987 ACR criteria for at least 6
             months prior to screening

          -  Patients who have inadequate response to MTX administered for at least 12 weeks before
             the beginning of screening period and on a stable dose.

        Exclusion Criteria:

          -  patients with active tuberculosis or latent tuberculosis based on current clinical
             symptoms, chest X-ray test and IFN-γ release assay at screening

          -  patients with any of the following concomitant diseases and/or history within 24 weeks
             before the first administration of investigational products in this study; Serious
             infectious disease, Opportunistic infection, Chronic or recurrent infectious disease

          -  patients with any seropositive result for hepatitis B or hepatitis C or HIV

          -  patients who have any of the following diseases; Sepsis, Demyelinating disorders,
             Lymphoproliferative disease, Infection with prosthetic joint, Autoimmune diseases
             other than rheumatoid arthritis
Clinical trial NCT02357459 (phase 3, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: fx006, placebo, tca ir 40
SMILES: OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Willingness and ability to comply with the study procedures and visit schedules and
             ability to follow verbal and written instructions

          -  Male or female >=40 years of age

          -  Has symptoms associated with OA of the index knee for at least 6 months prior to
             Screening

          -  Currently meets American College of Rheumatology (ACR) Criteria (clinical and
             radiological) for OA

          -  Kellgren-Lawrence (K-L) Grade 2 or 3 in the index knee per Screening X-ray

          -  Index knee pain for > 15 days over the last month

          -  Qualifying mean score on the 24-h average pain score (0-10 numeric rating scale)

          -  Body mass index (BMI) ≤ 40 kg/m2

          -  Willingness to abstain from use of restricted medications

        Exclusion Criteria:

          -  Any condition that could possibly confound the patient's assessment of index knee pain
             in judgement of the investigator (i.e., iIpsilateral hip OA, gout, radicular low back
             pain and hip pain that is referred to the knee that could cause misclassification,
             pain in any other area of the lower extremities or back that is equal or greater than
             the index knee pain)

          -  Fibromyalgia, Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing
             spondylitis, arthritis associated with inflammatory bowel disease

          -  History of infection in the index knee

          -  Clinical signs and symptoms of active knee infection or crystal disease of the index
             knee within 1 month of Screening

          -  Unstable joint within 12 months of screening

          -  IA corticosteroid (investigational or marketed) in any joint within 3 months of
             Screening

          -  IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of
             Screening

          -  Intramuscular (IM) or oral corticosteroids (investigational or marketed) within 1
             month of Screening

          -  Any other IA investigational drug/biologic within 6 months of Screening

          -  Prior use of FX006

          -  Women of child-bearing potential not using effective contraception or who are pregnant
             or nursing
Clinical trial NCT02357901 (phase 3, status: completed)
Conditions: opioid dependence, opioid related disorders
ICD codes: F11.20, F11.24, F11.281, F11.282, F11.288, F11.29, F11.21, F20.81, F21, F34.0, F34.1, F42.3, F45.0, F51.5
Drugs: suboxone, rbp-6000, placebo
SMILES: OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O, CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Currently meets Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
             (DSM-5) criteria for moderate or severe opioid use disorder

          -  By medical history has met DSM-5 criteria for moderate or severe opioid use disorder
             for the 3 months immediately prior to signing the informed consent form

          -  Is seeking medication-assisted treatment for opioid use disorder

          -  Is an appropriate candidate for opioid partial-agonist medication-assisted treatment
             in the opinion of the investigator or medically responsible physician

          -  Body mass index (BMI) of ≥ 18.0 to ≤ 35.0 kg/m^2

        Exclusion Criteria:

          -  Current diagnosis other than opioid use disorder requiring chronic opioid treatment

          -  Current substance use disorder as defined by DSM-5 criteria with regard to any
             substances other than opioids, cocaine, cannabis, tobacco, or alcohol.

          -  Positive urine drug screen (UDS) result at screening for cocaine or cannabis AND meets
             DSM-5 criteria for either moderate or severe cocaine or cannabis use disorder,
             respectively

          -  Meets DSM-5 criteria for moderate or severe alcohol use disorder

          -  Received medication-assisted treatment for opioid use disorder (e.g., methadone,
             buprenorphine) in the 90 days prior to providing written informed consent
Clinical trial NCT02358044 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: sofosbuvir, ribavirin, grazoprevir/elbasvir (100 mg/50 mg) fdc
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[C@@H](OC3=C(C=CC(=C3)C3=CNC(=N3)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Weigh ≥40 kg and ≤125 kg

          -  documented chronic HCV GT1, GT4, or GT6 infection

          -  cirrhosis/absence of cirrhosis defined by liver biopsy, Fibroscan, or FibroSure®

          -  either treatment naïve or PR Null Responder, PR Partial Responder, or PR Prior
             Relapser

          -  participant and partner both agree to use at least use at least 2 effective methods of
             contraception from at least 2 weeks prior to Day 1 and continue until up to 6 months
             after last dose of study drug, or longer if dictated by local regulations

        Exclusion Criteria:

          -  has evidence of decompensated liver disease

          -  is coinfected with hepatitis B virus (e.g. hepatitis B surface antigen positive) or
             human immunodeficiency virus

          -  history of malignancy ≤5 years prior to signing informed consent, or is under
             evaluation for other active or suspected malignancy

          -  has cirrhosis and liver imaging within 6 months of Day 1 showing evidence of
             hepatocellular carcinoma (HCC) or is under evaluation for HCC

          -  has any of the following conditions: immunologically-mediated disease, organ
             transplants other than cornea and hair, poor venous access that precludes routine
             peripheral blood sampling, history of gastric surgery or malabsorption disorders, or
             any medical condition requiring, or likely to require, chronic systemic administration
             of corticosteroids during the course of the trial, history of chronic hepatitis not
             caused by HCV
Clinical trial NCT02362503 (phase 3, status: active, not recruiting)
Conditions: hiv infections
ICD codes: Z21
Drugs: bms-663068
SMILES: COC1=C2C(=CN(COP(O)(O)=O)C2=C(N=C1)N1C=NC(C)=N1)C(=O)C(=O)N1CCN(CC1)C(=O)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Men and non-pregnant women with chronic HIV-1 infection

          -  Antiretroviral-experienced with documented historical or baseline resistance,
             intolerability, and/or contraindications to antiretrovirals in at least three classes

          -  Failing current antiretroviral regimen with a confirmed plasma HIV-1 RNA ≥ 400 c/mL
             (first value from Investigator, second from Screening labs)

          -  Must have ≤ 2 classes with at least 1 but no more than 2 fully-active antiretrovirals
             remaining which can be effectively combined to form a viable new regimen, based on
             current and/or documented historical resistance testing and tolerability and safety

          -  Able to receive ≥ 1 fully active approved antiretroviral as part of the OBT from Day 9
             onwards in the Randomized Cohort

          -  Subjects without any remaining fully active approved antiretroviral may be enrolled in
             the Non-Randomized Cohort

        Exclusion Criteria:

          -  Chronic untreated Hepatitis B virus (HBV) (however, patients with chronic treated HBV
             are eligible)

          -  HIV-2 infection

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 7 x ULN

          -  Alkaline Phosphatase > 5 x ULN

          -  Bilirubin ≥ 1.5 x Upper limit of normal (ULN) (unless subject is currently on
             atazanavir and has predominantly unconjugated hyperbilirubinemia)
Clinical trial NCT02362672 (phase 3, status: completed)
Conditions: low back pain, chronic pain
ICD codes: M54.50, M54.51, M54.59, G89.29, G89.4, R39.82, G89.22, G89.28, G89.21, G89.3
Drugs: nktr-181 bid tablets, placebo to match nktr-181 bid tablets
SMILES: [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CC[C@]2([H])OCCOCCOCCOCCOCCOCCOC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or non-pregnant, non-nursing female aged 18 to 75 years old

          -  Clinical diagnosis of moderate to severe, chronic non-neuropathic low back pain for at
             least six months

          -  Not experiencing adequate pain relief or have failed previous treatment with
             non-opioid analgesics

          -  Opioid analgesia is necessary

          -  Currently taking no more than 10 mg morphine sulfate equivalents per day of short
             acting opioids for 14 days prior to entry

          -  Females of child bearing potential must be using a highly effective form of birth
             control. All subjects must agree to use double-barrier contraception during
             participation in this study and for at least 2 months after the last dose of the study
             drug.

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Taking extended release or long-acting opioids within 6 months

          -  History of hypersensitivity, intolerance, or allergy to opioids

          -  Compression of spinal nerve root; spinal fracture, tumor, or abscess

          -  Surgical procedures on the low back in the last 12 months or facet nerve root block or
             radiofrequency ablation in the last 3 months

          -  Untreated moderate to severe sleep apnea
Clinical trial NCT02362984 (phase 3, status: terminated)
Conditions: acute ischemic stroke
ICD codes: I25.5, H47.013, H93.013, G45.9, H47.011, H47.012, H47.019
Drugs: placebo, dlbs1033
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    major technical hindrance in recruitment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects with age of 18-75 years .

          -  Has been diagnosed with acute ischemic stroke clinically confirmed by CT scan.

          -  Modified National Institutes of Health Stroke Scale (mNIHSS) score >= 5.

          -  Patients present at hospital and receiving first dose of study medication within 72
             hours after the onset of the stroke symptoms.

          -  Able to take oral medication.

        Exclusion Criteria:

          -  For females of childbearing potential: pregnancy and lactation period.

          -  History of or current hemorrhagic stroke (within the last 3 months).

          -  Transient ischemic stroke (TIA).

          -  Patients with seizure at the onset of stroke.

          -  History of serious head injury within the last 3 months.

          -  History of major surgery within the last 3 months.

          -  Serious cardiovascular conditions, such as myocardial infarction, CHF grade III and IV
             (NYHA classification), aorta dissection, and atrial fibrillation within the last 6
             months.

          -  Presence of severe renal or hepatic dysfunction

          -  Presence of acute or chronic infections.

          -  Thrombocytopenia (thrombocytes level < 150.000/ul).

          -  Patients with higher risks of bleeding.

          -  Uncontrolled hypertension (systolic blood pressure > 185 mmHg or diastolic blood
             pressure > 110 mmHg).

          -  Random plasma glucose >= 200 mg/dL.

          -  Current or regular use of oral anticoagulants, antiplatelets other than study
             medication, and herbal medicines.

          -  Hypersensitive to the investigational product(s).
Clinical trial NCT02364947 (phase 3, status: completed)
Conditions: alcohol dependence
ICD codes: F10.20, F10.24, F10.27, F10.280, F10.281, F10.282, F10.288
Drugs: nalmefene hydrochloride, placebo
SMILES: [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Japanese males and females aged 20 or above who have signed the informed consent form

          -  The patient has alcohol dependence, diagnosed according to Diagnostic and Statistical
             Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) and confirmed by
             Mini-international Neuropsychiatric Interview (M. I. N. I.)

          -  The patient has a drinking risk level of High or above (> 60 g for men and > 40 g for
             women) both at the Screening Visit and at the Randomization Visit .

        Exclusion Criteria:

          -  The patient with a current diagnosis or history of substance use disorders (except for
             alcohol, nicotine, and caffeine), according to DSM-IV-TR and confirmed by M. I. N. I.

          -  The patient has reported current use of, or has tested positive for, drugs of abuse
             (opiates, methadone, cocaine, amphetamines, barbiturates) at the screening test
Clinical trial NCT02364999 (phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: bevacizumab-pfizer, bevacizumab-eu, paclitaxel, carboplatin
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients age at least 18 years of age, or age of consent in the
             region.

          -  Newly diagnosed Stage IIIB or IV non-small cell lung cancer (according to Revised
             International System for Staging Lung Cancer criteria of 2010) or recurrent non-small
             cell lung cancer (NSCLC).

          -  Histologically or cytologically confirmed diagnosis of predominately non-squamous
             NSCLC.

          -  Be eligible to receive study treatment of bevacizumab, paclitaxel, and carboplatin
             based on local standard of care, for the treatment of advanced or metastatic
             non-squamous NSCLC.

        Exclusion Criteria:

          -  Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and
             mixed adenosquamous carcinomas of predominantly squamous nature.

          -  Evidence of a tumor that compresses or invades major blood vessels or tumor cavitation
             that is likely to bleed.

          -  Known sensitizing EGFR mutations (for example, deletion 19 or L858R) or EML4-ALK
             translocation positive mutations.

          -  Prior systemic therapy for NSCLC; prior neoadjuvant or adjuvant therapy is allowed if
             surgical resection for primary disease was performed.
Clinical trial NCT02365493 (phase 3, status: terminated)
Conditions: methicillin-resistant staphylococcus aureus
ICD codes: A41.02, A49.02, J15.212, Z86.14, Z22.322, B95.62
Drugs: beta-lactam
SMILES: [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O
Reason stopped: 
    recommendation of the data safety monitoring committee
  
Eligibility criteria:

        Inclusion Criteria:

          1. Age >= 18 years.

          2. ≥1 set of blood cultures positive for MRSA

          3. Able to be randomized within 72 hours of blood cultures being collected.

          4. Likely to remain as inpatient for 7 days following randomization

        Exclusion Criteria:

          1. Previous type 1 hypersensitivity reaction to ß-lactams

          2. Polymicrobial bacteraemia (not counting contaminants)

          3. Previous participation in the trial

          4. Known pregnancy

          5. Current β-lactam antibiotic therapy which cannot be ceased or substituted

          6. Participant's primary clinician unwilling to enrol patient

          7. Moribund (expected to die in next 48 hours with or without treatment)

          8. Treatment limitations which preclude the use of antibiotics Note that we are NOT
             planning to exclude participants with renal failure.